These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 16452657)

  • 1. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.
    Passini MA; Dodge JC; Bu J; Yang W; Zhao Q; Sondhi D; Hackett NR; Kaminsky SM; Mao Q; Shihabuddin LS; Cheng SH; Sleat DE; Stewart GR; Davidson BL; Lobel P; Crystal RG
    J Neurosci; 2006 Feb; 26(5):1334-42. PubMed ID: 16452657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.
    Cabrera-Salazar MA; Roskelley EM; Bu J; Hodges BL; Yew N; Dodge JC; Shihabuddin LS; Sohar I; Sleat DE; Scheule RK; Davidson BL; Cheng SH; Lobel P; Passini MA
    Mol Ther; 2007 Oct; 15(10):1782-8. PubMed ID: 17637720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
    Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
    Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
    Sondhi D; Peterson DA; Giannaris EL; Sanders CT; Mendez BS; De B; Rostkowski AB; Blanchard B; Bjugstad K; Sladek JR; Redmond DE; Leopold PL; Kaminsky SM; Hackett NR; Crystal RG
    Gene Ther; 2005 Nov; 12(22):1618-32. PubMed ID: 16052206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
    Kohlschütter A; Schulz A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.
    Sleat DE; Wiseman JA; El-Banna M; Kim KH; Mao Q; Price S; Macauley SL; Sidman RL; Shen MM; Zhao Q; Passini MA; Davidson BL; Stewart GR; Lobel P
    J Neurosci; 2004 Oct; 24(41):9117-26. PubMed ID: 15483130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression.
    Katz ML; Johnson GC; Leach SB; Williamson BG; Coates JR; Whiting REH; Vansteenkiste DP; Whitney MS
    Gene Ther; 2017 Apr; 24(4):215-223. PubMed ID: 28079862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.
    Chang M; Cooper JD; Sleat DE; Cheng SH; Dodge JC; Passini MA; Lobel P; Davidson BL
    Mol Ther; 2008 Apr; 16(4):649-56. PubMed ID: 18362923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.
    Sondhi D; Hackett NR; Peterson DA; Stratton J; Baad M; Travis KM; Wilson JM; Crystal RG
    Mol Ther; 2007 Mar; 15(3):481-91. PubMed ID: 17180118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease.
    Whiting REH; Jensen CA; Pearce JW; Gillespie LE; Bristow DE; Katz ML
    Exp Eye Res; 2016 May; 146():276-282. PubMed ID: 27039708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
    Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
    J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.
    Sondhi D; Peterson DA; Edelstein AM; del Fierro K; Hackett NR; Crystal RG
    Exp Neurol; 2008 Sep; 213(1):18-27. PubMed ID: 18639872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A frame shift mutation in canine TPP1 (the ortholog of human CLN2) in a juvenile Dachshund with neuronal ceroid lipofuscinosis.
    Awano T; Katz ML; O'Brien DP; Sohar I; Lobel P; Coates JR; Khan S; Johnson GC; Giger U; Johnson GS
    Mol Genet Metab; 2006 Nov; 89(3):254-60. PubMed ID: 16621647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
    Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
    Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.
    Worgall S; Sondhi D; Hackett NR; Kosofsky B; Kekatpure MV; Neyzi N; Dyke JP; Ballon D; Heier L; Greenwald BM; Christos P; Mazumdar M; Souweidane MM; Kaplitt MG; Crystal RG
    Hum Gene Ther; 2008 May; 19(5):463-74. PubMed ID: 18473686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis.
    Whiting REH; Pearce JW; Vansteenkiste DP; Bibi K; Lim S; Robinson Kick G; Castaner LJ; Sinclair J; Chandra S; Nguyen A; O'Neill CA; Katz ML
    Exp Eye Res; 2020 Aug; 197():108130. PubMed ID: 32622066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis.
    Sleat DE; El-Banna M; Sohar I; Kim KH; Dobrenis K; Walkley SU; Lobel P
    Mol Genet Metab; 2008 Jun; 94(2):222-33. PubMed ID: 18343701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
    Tracy CJ; Whiting RE; Pearce JW; Williamson BG; Vansteenkiste DP; Gillespie LE; Castaner LJ; Bryan JN; Coates JR; Jensen CA; Katz ML
    Exp Eye Res; 2016 Nov; 152():77-87. PubMed ID: 27637672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.